1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Aggressive Lymphoma: new trials by email Literature Review of Aggressive Lymphoma trials Research Report on Aggressive Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Of The Selective PKC-β Inhibitor MS- 553 MS-553, acalabrutinib, venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 60 | 2018-05-25 | 2025-04-10 |
Leukemia, Lymphocytic, Chronic, B-Cell (1)
Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (1) · acalabrutinib (1) · obinutuzumab (1) · venetoclax (1)
MingSight Pharmaceuticals, Inc (1)
United States (1)